A review of perindopril in the reduction of cardiovascular events

Vascular Health and Risk Management

Volumn 2, Issue 2, 2006, Pages 117-124

  Campbell, Duncan J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Coronary heart disease; Heart failure; Hypertension; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; NITRATE; PERINDOPRIL; PLACEBO;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDICATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 33744999224     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.2.117     Document Type: Review

References (46)

1. Asmar RG, London GM, O'Rourke ME, et al. 2001. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension, 38:922-6.
2. Beevers G, Lip GY, O'Brien E. 2001. ABC of hypertension: The pathophysiology of hypertension. Br Med J, 322:912-16.
3. Bijlstra PJ, Smits P, Lutterman JA, et al. 1995. Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome. J Cardiovasc Pharmacol, 25:658-64.
4. [BPLTT] Blood Pressure Lowering Treatment Trialists' Collaboration. 2005. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med, 165:1410-19.
5. [CAFE] The CAFE Investigators; for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) investigators. 2006. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113:1213-25.
6. Campbell DJ, Kladis A, Duncan AM. 1994. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension, 23:439-49.
7. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
8. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
9. Dahlof B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366:895-906.
10. Daly CA, Fox KM, Remme WJ, et al. 2005. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J, 26:1369-78.
11. de Luca N, Mallion JM, O'Rourke MF, et al. 2004. Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens, 17:660-7.
12. [EUROPA] European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. 2003. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362:782-8.
13. Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. 2006. Effects of angiotensin-converting enzyme inhibition with perindopril on left vascular remodeling and clinical outcome: results of the randomized Perindopril and Remodelling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med, 166:659-66.
14. Flather MD, Yusuf S, Kober L, et al. 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left- ventricular dysfunction: a systematic overview of data from individual patients. Lancet, 355:1575-81.
15. Guyton AC, Hall JE, Coleman TG, et al. 1995. The dominant role of the kidneys in long term arterial pressure regulation in normal and hypertensive states. In: Laragh JH and Brenner BM (eds). Hypertension: pathophysiology, diagnosis, and management. New York, Raven Pr Ltd. p 1311-26.
16. Hansson L, Lindholm LH, Niskanen L, et al. 1999. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 353:611-16.
17. [HOPE] Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.
18. Hunt SA, Abraham WT, Chin MH, et al. 2005. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation, 112:1825-52.
19. Ikram MK, Witteman JCM, Vingerling JR, et al. 2006. Retinal vessel diameters and risk of hypertension: the Rotterdam study. Hypertension, 47:189-94.
20. Johnson RJ, Herrera-Acosta J, Schreiner GF, et al. 2002. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med, 346:913-23.
21. Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363:2022-31.
22. Keuper W, Verheugt FW. 2005. Hotline sessions of the 27th European congress of cardiology. Eur Heart J, 26:2596-9.
23. King DE, Egan BM, Mainous AG, 3rd, et al. 2004. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich), 6:562-8.
24. Landray MJ, Edmunds E, Li-Saw-Hee FL, et al. 2002. Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. Qjm, 95:165-71.
25. Lewis EJ, Hunsicker LG, Bain RP, et al. 1993. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 329:1456-62.
26. Lip GY, Blann AD, Beevers DG. 1999. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J Hypertens, 17:1203-7.
27. Lip GY, Blann AD, Zarifis J, et al. 1995. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens, 13:1674-8.
28. Mark AL. 1984. Structural changes in resistance and capacitance vessels in borderline hypertension. Hypertension, 6(Suppl III):III-69-III-73.
29. Mogensen CE, Viberti G, Halimi S, et al. 2003. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension, 41:1063-71.
30. Noon JP, Walker BR, Webb DJ, et al. 1997. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest, 99:1873-9.
31. [PEACE] PEACE Trial Investigators. 2004. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 351:2058-68.
32. Pitt B. 2004. ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med, 351:2115-17.
33. Poulter NR, Wedel H, Dahlof B, et al. 2005. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 366:907-13.
34. [PROGRESS] PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358:1033-41.
35. [PROGRESS] PROGRESS Collaborative Group. 2003. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J, 24:475-84.
36. [PSC] Prospective Studies Collaboration. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360:1903-13.
37. Remme WJ, Swedberg K. 2001. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J, 22:1527-60.
38. Safar ME, Boudier HS. 2005. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension, 46:205-9.
39. Simon G. 2004. Pathogenesis of structural vascular changes in hypertension. J Hypertens, 22:3-10.
40. Skov K, Mulvany MJ. 2004. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand, 181:397-405.
41. Watanabe S, Tagawa T, Yamakawa K, et al. 2005. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol, 25:2376-80.
42. Weber MA, Julius S, Kjeldsen SE, et al. 2004. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 363:2049-51.
43. [WHO] World Health Organization. 2002. World Health Report 2002: reducing risks, promoting healthy life. Geneva, WHO.
44. Wong TY, Shankar A, Klein R, et al. 2004. Prospective cohort study of retinal vessel diameters and risk of hypertension. Br Med J, 329:79.
45. Zandi-Nejad K, Luyckx VA, Brenner BM. 2006. Adult hypertension and kidney disease. The role of fetal programming. Hypertension, 47:502-8.
46. Zeitz CJ, Campbell DJ, Horowitz JD. 2003. Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension, 41:482-7.